{
  "docId": "019de075-f154-767b-9f07-479a2da3f64b",
  "docSlug": "d4796e91221d5758021de97ee63957e0",
  "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 69,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a human anatomy diagram to map specific cancer types to their respective organ systems.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/32",
  "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b",
  "deckJsonHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b.json",
  "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Covers all indications included in Ph1/2 ELUCIDATE trial; Patient counts for each subtype based on EvaluatePharma Epidemiology 2022 and primary inclusion criteria for ELUCIDATE Ph 1/2 trial. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; *Excludes currently actionable driver mutations such as ALK, EGFR, BRAF, ROS1, RET and MET",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09121561-7fb4-4a22-8ccb-bd8346b244b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.975,
        "w": 0.265,
        "x": 0.248,
        "y": 0.185
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eb5d9ea-4ea3-46a0-98dd-8aeeacd69fa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.07,
        "y": 0.2
      },
      "kind": "list",
      "text": "5K Head & Neck Cancer; 12K Breast Cancer; 29K Non-small Cell Lung Cancer; 8K Pancreatic Cancer; 6K Ovarian Cancer; 15K Colorectal Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41609f03-b704-4ca1-91e7-e1751eb07bf4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.68,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~75K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "167507f4-3161-425a-84c8-5dc14ad19ac4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for patient sub-groups included in ELUCIDATE trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "525cf038-6bdf-47dc-8aaa-a7e24d4f66c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d851f0e-9b30-40d5-8abd-1d9fa2de4a46",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 69,
      "from": 8,
      "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 69,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d",
      "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.",
      "position": 1,
      "objective": "Why is Exscientia's approach to precision medicine effective?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}